认知颠覆战，当Alnylam逼近4000亿

Core Insights - Alnylam's RNAi therapy Amvuttra has achieved remarkable sales growth, reaching $492 million in its first quarter post-approval for ATTR-CM, a 114% increase year-over-year, significantly surpassing analyst expectations of $365 million [1][4] - The company has raised its full-year revenue guidance from $2.05-2.25 billion to $2.65-2.8 billion, driven by the strong performance of Amvuttra [1][4] - Alnylam's CEO indicated that Amvuttra's approval marks a new growth phase for the company, with expectations of achieving sustainable non-GAAP profitability this year [2][5] Sales Performance - Amvuttra's sales performance in the second quarter was driven by approximately 1,400 patients receiving treatment, contributing $150 million in revenue [4] - The TTR product portfolio, including Amvuttra and another RNAi therapy Onpattro, has seen its revenue guidance increased from $1.6-1.73 billion to $2.18-2.28 billion [4] Market Dynamics - The ATTR-CM market is projected to exceed $11.2 billion by 2030, with significant unmet clinical needs due to limited treatment options [3] - Despite Tafamidis's established market presence, Amvuttra has quickly gained traction, with about 50% of its current patients being treated as first-line therapy [6][8] Competitive Landscape - Alnylam's strategy has successfully challenged the long-standing dominance of Pfizer in the ATTR-CM market, with expectations that Amvuttra could capture a significant market share [10][11] - The rapid acceptance of Amvuttra by physicians and its inclusion in insurance coverage have been key factors in its swift market penetration [7][8] Future Outlook - Alnylam's proactive approach in market access and patient payment strategies has positioned it favorably against larger pharmaceutical companies [11][12] - The company's experience and execution in commercializing Amvuttra may serve as a model for other biotech firms aiming to compete with established players in the industry [13]